Prostate Cancer International is
for 2011 by Great NonProfits
An article by Crawford and Arangua on page 3 of the June issue of AUA News provides a series of “take home messages” for attendees of the annual meeting of the American Urological Association in Washington, DC, last month.
Filed under: Management, Treatment | Tagged: annual meeting, AUA, localized | 4 Comments »
In February this year we reported initial 4- and 5-year follow-up data from two US-based research teams on the use of stereotactic body radiation therapy (SBRT or CyberKnife radiation) as a treatment for prostate cancer. A new study from a Korean research group appears to confirm the earlier findings.
Filed under: Diagnosis, Management, Treatment | Tagged: body, localized, outcome, SBRT, stereotactic | 3 Comments »
A recent article in the Cleveland Clinic Journal of Medicine provides a summary of the way three leading specialists at this institution approach the diagnosis and management of localized prostate cancer today.
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: Diagnosis, localized, Treatment | Leave a Comment »
A biopharmaceutical company called Advantagene, Inc. announced last Thursday that it has reached agreement with the U.S. Food and Drug Administration regarding the conduct of a Phase III clinical trial of a vaccine-like treatment called ProstAtak™ — in combination with standard therapy — in the treatment of patients with newly diagnosed prostate cancer.
Filed under: Drugs in development, Management | Tagged: AdV-tk, gene suicide, immunotherapy, localized, ProstAtak, vaccine, valacyclovir | Leave a Comment »
Data from a series of Japanese patients continue to help us to understand the risks and benefits of first-line treatment with high-intensity focused ultrasound (HIFU) for men initially diagnosed with localized prostate cancer and followed for up to 7 years.
Filed under: Management, Treatment | Tagged: HIFU, high-intensity focused ultrasound, localized | 2 Comments »
The abstract for the presentation of the resulsts of the REDEEM trial (to be presented on Thursday at the Gentourinary Cancer Symposium in Orlando) was published this evening on the ASCO web site. The data show that dutasteride delayed progression of prostate cancer in a well-defined group of patients compared to placebo therapy.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: dutasteride, localized, low risk, REDEEM | 9 Comments »
The Surgical Prostatectomy versus Interstitial Radiation Intervention Trial or SPIRIT was a Phase III, partially randomized clinical trial, conducted in the U.S.A. and Canada, and designed to compare radical prostatectomy (RP) and brachytherapy (BT) as first-line treatments for men with localized prostate cancer.
Filed under: Management, Treatment | Tagged: brachytherapy, HRQOL, localized, outcome, quality of life, radical prostatectomy, SPIRIT | Leave a Comment »
A new paper in the Scandinavian Journal of Urology and Nephrology has provided detailed information about the design and conduct of an ongoing, prospective, non-randomized trial comparing open radical retropubic prostatectomy (RRP) to robot-assisted laparoscopic radical prostatectomy (RALP) in treatment of localized prostate cancer.
Filed under: Management, Treatment | Tagged: comparative, effectiveness, localized, open, RALP, robot-assisted, RRP, surgery | Leave a Comment »
There is an interesting summary of the major, first-line management options for localized prostate cancer in today’s Washington Post. It has been prepared by the Consumer’s Union (publisher of Consumer Reports) as part of their Consumer Reports Insights series.
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: Consumers Union, localized, summary, Treatment | Leave a Comment »
Awareness of brachytherapy as a treatment for localized prostate cancer was revolutionized in the U.S. in 1996 — not by a doctor but by a patient.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active surveillance, Australia, Bertrand, localized | 1 Comment »
A new report from researchers at the University of Florida Proton Therapy Institute offers us some additional information on the short-term outcomes of first-line treatment with image-guided proton beam radiation therapy (PBRT) for localized prostate cancer.
Filed under: Management, Treatment | Tagged: localized, outcome, PBRT, proton beam radiation | Leave a Comment »
The need for patients diagnosed with early stage prostate cancer to be highly involved in the decision as to which form of management they wish to be given is well understood. However, there has been a relative dearth of data on why patients actually make their individual decisions.
Filed under: Diagnosis, Management, Treatment | Tagged: choice, first line, intermediate, localized, low, Management, patient, risk, Treatment | 2 Comments »
In the past, high-dose-rate (HDR) brachytherapy has been used alone or (more commonly) in combination with external beam radiation therapy (EBRT) for the treatment of localized prostate cancer. However, when used alone, it has been necessary to treat the patient with several sessions of HDR brachytherapy.
Filed under: Management, Treatment | Tagged: brachtherapy, HDR, high-dose-rate, intermediate risk, localized, low risk, single dose | Leave a Comment »
At the beginning of November, we commented on a re-analysis of the PLCO data by Crawford et al. — a re-analysis that focused on the impact of co-morbidities on treatment and outcomes over time.
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: Co-morbidity, early detection, localized, low risk, Management, screening | Leave a Comment »
A new report from Memorial Sloan-Kettering Cancer Center has documented patient outcomes at 10 years after high-dose, intensity-modulated radiation therapy (IMRT) for men initially diagnosed with clinically localized prostate cancer.
Filed under: Management, Treatment | Tagged: high-dose, IMRT, intensity-modulated radtiation therapy, localized, outcome | 2 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site